Voyager Acquisition Corp./Cayman Islands 8-K

What Happened Voyager Acquisition Corp. (VACH) filed an 8-K (Item 7.01) disclosing that VERAXA Biotech AG — a Swiss company — will issue a press release on March 2, 2026 announcing that VERAXA shareholders approved a merger and the issuance of new shares to Voyager Acquisition Corp. The 8-K, filed February 27, 2026, attaches that press release as Exhibit 99.1 and was furnished under Regulation FD.

Key Details

• Filing date: February 27, 2026 (Form 8-K, Item 7.01 Disclosure).
• Press release date: March 2, 2026 (VERAXA to announce shareholder approval).
• Parties: VERAXA Biotech AG (Swiss company) and Voyager Acquisition Corp. (Cayman Islands SPAC).
• Event: VERAXA shareholders approved the merger and issuance of new shares to the SPAC; press release attached as Exhibit 99.1.

Why It Matters Shareholder approval is a material step in completing a SPAC business combination. This disclosure signals progress toward completing the merger and the issuance of shares to Voyager, which can affect Voyager’s ownership structure and path to operating as the combined company. Investors should monitor follow-up SEC filings and the press release for transaction terms, closing conditions, and any additional material disclosures.